Old Web
English
Sign In
Acemap
>
authorDetail
>
L.V. Sequist
L.V. Sequist
Harvard University
Internal medicine
Oncology
Medicine
Pemetrexed
first line
3
Papers
0
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
OFP01.02 KEYNOTE-021 Cohort G Long-Term Follow-up: First-Line (1L) Pemetrexed and Carboplatin (PC) with or without Pembrolizumab for Advanced Nonsquamous NSCLC
2021
Journal of Thoracic Oncology
Mark M. Awad
Shirish M. Gadgeel
Hossein Borghaei
Amita Patnaik
J. Chih-Hsin Yang
Steven Francis Powell
Ryan D. Gentzler
Renato Martins
James P. Stevenson
Mehmet Altan
Shadia I. Jalal
Amit Panwalkar
Matthew A. Gubens
L.V. Sequist
Sanatan Saraf
B. Zhao
Bilal Piperdi
Corey J. Langer
Show All
Source
Cite
Save
Citations (0)
P47.11 COMPEL: Chemotherapy With/Without Osimertinib in Patients With EGFRm Advanced NSCLC and Progression on First-Line Osimertinib
2021
Journal of Thoracic Oncology
L.V. Sequist
N. Peled
Amanda Tufman
L. Servidio
J. Li
R. Taylor
Jiuran Zhao
Show All
Source
Cite
Save
Citations (0)
Integration of EGFR Inhibition With Radiation-Based Multimodality Treatment in Stage III EGFR Mutant NSCLC.
2021
International Journal of Radiation Oncology Biology Physics
Henning Willers
Andrew J. Piper-Vallillo
Julia K. Rotow
J.P. Marcoux
Alona Muzikansky
Scott J. Swanson
Michael Lanuti
Zofia Piotrowska
Florence K. Keane
David Kozono
Raymond H. Mak
L.V. Sequist
Show All
Source
Cite
Save
Citations (0)
1